Literature DB >> 25806277

Mechanisms of immune response regulation in lung cancer.

Joanna Domagala-Kulawik1, Iwona Osinska1, Grazyna Hoser1.   

Abstract

Lung cancer is a leading cause of cancer deaths. As a solid tumor with low antigenicity and heterogenic phenotype lung cancer evades host immune defense. The cytotoxic anticancer effect is suppressed by a complex mechanism in tumor microenvironment. The population of regulatory T cells (Tregs) plays a crucial role in this inhibition of immune response. Tregs are defined by presence of forkhead box P3 (Foxp3) molecule. The high expression of Foxp3 was found in lung cancer cells and in tumor infiltrating lymphocytes (TIL). Cytotoxic T-lymphocyte antigen 4 (CTLA4) is constitutively expressed on Tregs and suppresses T cell activation. The elevated CTLA4 expression in lymphocytes in patients with lung cancer was found. Recently the antibodies blocking CTLA4 showed some clinical efficacy in patients with lung cancer. Cancer cells and immune cells release many cytokines capable to show suppressive immune effect in cancer microenvironment. The most active are transforming growth factorβ (TGFβ) and IL-10. The pleiotropic function of Th17 population is TGFβ related. The myeloid lineage of suppressor cells in lung cancer is represented by tumor associated macrophages (TAM) with phenotype of M2 macrophages and some regulatory properties with releasing amounts of IL-10 and TGFβ. The myeloid derived suppressor cells (MDSCs) control cytotoxic T cell activity in mechanisms which are highly dependent on the context of tumor environment. The mechanisms of anticancer immune response regulation need further investigation as an important target to new way of treatment.

Entities:  

Keywords:  Lung cancer; Th17 cells; cytotoxic T-lymphocyte antigen 4 (CTLA4); myeloid derived suppressor cells (MDSCs); regulatory T cells (Tregs)

Year:  2014        PMID: 25806277      PMCID: PMC4367608          DOI: 10.3978/j.issn.2218-6751.2013.11.03

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  72 in total

1.  Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer.

Authors:  Lunxu Liu; Dongxia Ge; Lin Ma; Jiandong Mei; Sen Liu; Qiuyang Zhang; Fuqiang Ren; Hu Liao; Qiang Pu; Tao Wang; Zongbing You
Journal:  J Thorac Oncol       Date:  2012-07       Impact factor: 15.609

2.  Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC).

Authors:  Nasrollah Erfani; Shayesteh Mofakhami Mehrabadi; Mohammad Ali Ghayumi; Mohammad Reza Haghshenas; Zahra Mojtahedi; Abbas Ghaderi; Davar Amani
Journal:  Lung Cancer       Date:  2012-05-17       Impact factor: 5.705

Review 3.  The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group.

Authors:  Erik Thunnissen; Keith M Kerr; Felix J F Herth; Sylvie Lantuejoul; Mauro Papotti; Robert C Rintoul; Giulio Rossi; Birgit G Skov; Birgit Weynand; Lukas Bubendorf; Grünberg Katrien; Leif Johansson; Fernando López-Ríos; Vincent Ninane; Włodzimierz Olszewski; Helmut Popper; Sauleda Jaume; Philipp Schnabel; Luc Thiberville; Florian Laenger
Journal:  Lung Cancer       Date:  2011-12-03       Impact factor: 5.705

4.  Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer.

Authors:  Hui Liu; Tiantuo Zhang; Jin Ye; Hongtao Li; Jing Huang; Xiaodong Li; Benquan Wu; Xubing Huang; Jinghui Hou
Journal:  Cancer Immunol Immunother       Date:  2012-03-29       Impact factor: 6.968

5.  Expression of Fas antigen in the cells from bronchoalveolar lavage fluid (BALF).

Authors:  J Domagała-Kulawik; P Droszcz; I Kraszewska; R Chazan
Journal:  Folia Histochem Cytobiol       Date:  2000       Impact factor: 1.698

Review 6.  Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience.

Authors:  Håkan Mellstedt; Johan Vansteenkiste; Nick Thatcher
Journal:  Lung Cancer       Date:  2011-04-06       Impact factor: 5.705

7.  Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.

Authors:  Rebecca P Petersen; Michael J Campa; Justin Sperlazza; Debbi Conlon; Mary-Beth Joshi; David H Harpole; Edward F Patz
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

8.  Functional genetic variations in the IL-23 receptor gene are associated with risk of breast, lung and nasopharyngeal cancer in Chinese populations.

Authors:  Jian Zheng; Lan Jiang; Liyuan Zhang; Lei Yang; Jieqiong Deng; Yonghe You; Na Li; Hongchun Wu; Wei Li; Jiachun Lu; Yifeng Zhou
Journal:  Carcinogenesis       Date:  2012-10-06       Impact factor: 4.944

Review 9.  Targeted therapies for non-small cell lung cancer.

Authors:  Wolfram C M Dempke; Tamas Suto; Martin Reck
Journal:  Lung Cancer       Date:  2009-11-14       Impact factor: 5.705

10.  Therapeutical measures to control airway tolerance in asthma and lung cancer.

Authors:  Katerina Andreev; Anna Graser; Anja Maier; Stephanie Mousset; Susetta Finotto
Journal:  Front Immunol       Date:  2012-07-26       Impact factor: 7.561

View more
  21 in total

1.  Human lung tumor FOXP3+ Tregs upregulate four "Treg-locking" transcription factors.

Authors:  Tatiana Akimova; Tianyi Zhang; Dmitri Negorev; Sunil Singhal; Jason Stadanlick; Abhishek Rao; Michael Annunziata; Matthew H Levine; Ulf H Beier; Joshua M Diamond; Jason D Christie; Steven M Albelda; Evgeniy B Eruslanov; Wayne W Hancock
Journal:  JCI Insight       Date:  2017-08-17

Review 2.  Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.

Authors:  David P Carbone; David R Gandara; Scott J Antonia; Christoph Zielinski; Luis Paz-Ares
Journal:  J Thorac Oncol       Date:  2015-07       Impact factor: 15.609

3.  Fusion with human lung cancer cells elongates the life span of human umbilical endothelial cells and enhances the anti-tumor immunity.

Authors:  Xiyan Mu; Chunju Fang; Jing Zhou; Yufeng Xi; Li Zhang; Yuquan Wei; Tao Yi; Yang Wu; Xia Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2015-07-03       Impact factor: 4.553

4.  IL-21 polymorphisms rs907715 and rs2221903 are associated with decreased non-small cell lung cancer susceptibility.

Authors:  Lanping Liu; Fang Shi; Shanshan Li; Xiuju Liu; Lili Wei; Jian Zhang; Xiao Ju; Jinming Yu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

5.  Small cell lung cancer: Recruitment of macrophages by circulating tumor cells.

Authors:  Gerhard Hamilton; Barbara Rath; Lukas Klameth; Maximilan J Hochmair
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

Review 6.  Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis.

Authors:  Erin A Marshall; Kevin W Ng; Sonia H Y Kung; Emma M Conway; Victor D Martinez; Elizabeth C Halvorsen; David A Rowbotham; Emily A Vucic; Adam W Plumb; Daiana D Becker-Santos; Katey S S Enfield; Jennifer Y Kennett; Kevin L Bennewith; William W Lockwood; Stephen Lam; John C English; Ninan Abraham; Wan L Lam
Journal:  Mol Cancer       Date:  2016-10-27       Impact factor: 27.401

7.  How to evaluate the immune status of lung cancer patients before immunotherapy.

Authors:  Joanna Domagala-Kulawik; Agata Raniszewska
Journal:  Breathe (Sheff)       Date:  2017-12

8.  Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients.

Authors:  Oscar Arrieta; Edgar Montes-Servín; Juan-Manuel Hernandez-Martinez; Andrés F Cardona; Eibar Casas-Ruiz; José C Crispín; Daniel Motola; Diana Flores-Estrada; Lourdes Barrera
Journal:  Oncotarget       Date:  2017-10-24

9.  Elevated Foxp3/CD8 Ratio in Lung Adenocarcinoma Metastatic Lymph Nodes Resected by Transcervical Extended Mediastinal Lymphadenectomy.

Authors:  Joanna Domagala-Kulawik; Iwona Kwiecien; Juliusz Pankowski; Monika Pasieka-Lis; Dominika Wolosz; Marcin Zielinski
Journal:  Biomed Res Int       Date:  2017-08-02       Impact factor: 3.411

10.  Elevated regulatory T cells, surface and intracellular CTLA-4 expression and interleukin-17 in the lung cancer microenvironment in humans.

Authors:  Iwona Kwiecien; Anna Stelmaszczyk-Emmel; Malgorzata Polubiec-Kownacka; Dariusz Dziedzic; Joanna Domagala-Kulawik
Journal:  Cancer Immunol Immunother       Date:  2016-11-19       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.